# 2026-23692: FDA Drafts Study Guides to Help Generic Drugs Prove Equivalence

2026-23692, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-20, effective Submit either electronic or written comments on these draft guidances by January 19, 2027 to ensure that the Agency considers your comment on these draft guidances before it begins work on the final version of these guidances.; PRIA reads it as touching household money (as of 2026-11-20).

- Canonical: https://policyrisk.com/federal-register/2026-23692
- As of: 2026-11-20
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23692
- Title: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 75332
- Published: 2026-11-20
- Effective: Submit either electronic or written comments on these draft guidances by January 19, 2027 to ensure that the Agency considers your comment on these draft guidances before it begins work on the final version of these guidances.
- Comments close: 2027-01-19
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-20

## In one line

FDA Drafts Study Guides to Help Generic Drugs Prove Equivalence

## Summary

The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like brand-name ones. If you’re in the drug business, these guides show you exactly what the FDA expects, making the approval process smoother and faster. You’ve got until January 19, 2027, to send your feedback before these guides become final—saving time and possibly money down the road!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.

## Effects PRIA read

- New draft guidances for specific drugs: benefit, medium. FDA posted new draft product-specific guidances that give product-specific recommendations on designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The new drafts apply to products containing Aficamten; Barium sulfate; Berotralstat dihydrochloride; Bumetanide;…
- Revised draft guidances for listed drugs: benefit, medium. FDA posted revised draft product-specific guidances with recommendations on BE study design for ANDAs for products containing Albuterol sulfate; Azathioprine; Betaxolol hydrochloride; Bupropion hydrochloride; Dextromethorphan hydrobromide; Carbinoxamine maleate; Estrogens, conjugated; Gabapentin en…
- 60‑day public comment deadline (Jan 19, 2027): benefit, low. Stakeholders may submit electronic or written comments on these draft guidances and must submit them by January 19, 2027 for FDA to consider them before it begins work on the final versions. Comments submitted to https://www.regulations.gov will be posted publicly unless submitted as written/paper…
- Guidances are non‑binding; alternatives allowed: benefit, low. FDA states that these draft guidances, when finalized, will represent the Agency's current thinking but do not establish any rights and are not binding. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
- FDA will consider cost comments under EO 14192: benefit, low. FDA will consider comments on costs or cost savings the guidance may generate as it develops final guidances, consistent with Executive Order 14192. Stakeholders can submit cost or cost‑savings information for FDA's consideration.

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-14967](https://policyrisk.com/federal-register/2025-14967): Requirements for Additional Traceability Records for Certain Foods: Compliance Date Extension, 2025-08-07

## Sources
- [2026-23692 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/20/2026-23692/product-specific-guidances-draft-and-revised-draft-guidances-for-industry-availability)
- [2026-23692 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-20/pdf/2026-23692.pdf)

## Related
- [Previous: 2026-23687, Board of Overseers of the Malcolm Baldrige National Quality Award](https://policyrisk.com/federal-register/2026-23687)
- [Next: 2026-23693, Submission for OMB Review; Comment Request](https://policyrisk.com/federal-register/2026-23693)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23692 (as of 2026-11-20).
